165 related articles for article (PubMed ID: 37474204)
1. MDM2-Targeting Reassembly Peptide (TRAP) Nanoparticles for p53-Based Cancer Therapy.
Li F; Chen D; Sun Q; Wu J; Gan Y; Leong KW; Liang XJ
Adv Mater; 2023 Nov; 35(45):e2305164. PubMed ID: 37474204
[TBL] [Abstract][Full Text] [Related]
2. AKT regulates NPM dependent ARF localization and p53mut stability in tumors.
Hamilton G; Abraham AG; Morton J; Sampson O; Pefani DE; Khoronenkova S; Grawenda A; Papaspyropoulos A; Jamieson N; McKay C; Sansom O; Dianov GL; O'Neill E
Oncotarget; 2014 Aug; 5(15):6142-67. PubMed ID: 25071014
[TBL] [Abstract][Full Text] [Related]
3. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
Gamble LD; Kees UR; Tweddle DA; Lunec J
Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
[TBL] [Abstract][Full Text] [Related]
4. ARF function does not require p53 stabilization or Mdm2 relocalization.
Korgaonkar C; Zhao L; Modestou M; Quelle DE
Mol Cell Biol; 2002 Jan; 22(1):196-206. PubMed ID: 11739734
[TBL] [Abstract][Full Text] [Related]
5. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
Amir S; Ma AH; Shi XB; Xue L; Kung HJ; Devere White RW
PLoS One; 2013; 8(4):e61064. PubMed ID: 23585871
[TBL] [Abstract][Full Text] [Related]
6. Abnormal MDMX degradation in tumor cells due to ARF deficiency.
Li X; Gilkes D; Li B; Cheng Q; Pernazza D; Lawrence H; Lawrence N; Chen J
Oncogene; 2012 Aug; 31(32):3721-32. PubMed ID: 22120712
[TBL] [Abstract][Full Text] [Related]
7. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
[TBL] [Abstract][Full Text] [Related]
8. Regulation of the p14ARF-Mdm2-p53 pathway: an overview in breast cancer.
Agrawal A; Yang J; Murphy RF; Agrawal DK
Exp Mol Pathol; 2006 Oct; 81(2):115-22. PubMed ID: 16919268
[TBL] [Abstract][Full Text] [Related]
9. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse.
Carr J; Bell E; Pearson AD; Kees UR; Beris H; Lunec J; Tweddle DA
Cancer Res; 2006 Feb; 66(4):2138-45. PubMed ID: 16489014
[TBL] [Abstract][Full Text] [Related]
10. Sumoylation induced by the Arf tumor suppressor: a p53-independent function.
Tago K; Chiocca S; Sherr CJ
Proc Natl Acad Sci U S A; 2005 May; 102(21):7689-94. PubMed ID: 15897463
[TBL] [Abstract][Full Text] [Related]
11. Farnesoid X receptor functions in cervical cancer via the p14
Huang X; Wang B; Shen H; Huang D; Shi G
Mol Biol Rep; 2022 May; 49(5):3617-3625. PubMed ID: 35347542
[TBL] [Abstract][Full Text] [Related]
12. Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line.
Vaskivuo L; Rysä J; Koivuperä J; Myllynen P; Vaskivuo T; Chvalova K; Serpi R; Savolainen ER; Puistola U; Vähäkangas K
Toxicol Appl Pharmacol; 2006 Oct; 216(1):89-97. PubMed ID: 16797627
[TBL] [Abstract][Full Text] [Related]
13. Expression of p14ARF overcomes tumor resistance to p53.
Lu W; Lin J; Chen J
Cancer Res; 2002 Mar; 62(5):1305-10. PubMed ID: 11888896
[TBL] [Abstract][Full Text] [Related]
14. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
15. Escape from p53-mediated tumor surveillance in neuroblastoma: switching off the p14(ARF)-MDM2-p53 axis.
Van Maerken T; Vandesompele J; Rihani A; De Paepe A; Speleman F
Cell Death Differ; 2009 Dec; 16(12):1563-72. PubMed ID: 19779493
[TBL] [Abstract][Full Text] [Related]
16. p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo.
Tolbert D; Lu X; Yin C; Tantama M; Van Dyke T
Mol Cell Biol; 2002 Jan; 22(1):370-7. PubMed ID: 11739748
[TBL] [Abstract][Full Text] [Related]
17. Contribution of two independent MDM2-binding domains in p14(ARF) to p53 stabilization.
Lohrum MA; Ashcroft M; Kubbutat MH; Vousden KH
Curr Biol; 2000 May; 10(9):539-42. PubMed ID: 10801444
[TBL] [Abstract][Full Text] [Related]
18. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
19. Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo.
Chen Z; Lin Y; Barbieri E; Burlingame S; Hicks J; Ludwig A; Shohet JM
Neoplasia; 2009 Aug; 11(8):753-62. PubMed ID: 19649205
[TBL] [Abstract][Full Text] [Related]
20. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF.
Wang P; Greiner TC; Lushnikova T; Eischen CM
Oncogene; 2006 Jun; 25(26):3708-18. PubMed ID: 16491126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
